furosemide has been researched along with tacrolimus in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Akra, I; Asai, P; Aswad, S; Bogaard, T; Khetan, U; Mendez, R; Mendez, RG; Satterthwaite, R; Shidban, H; Sunga, V | 1 |
| Balaji, V; Jurewicz, WA; Lord, R; Moore, R; Morris-Stiff, G; Ostrowski, K; Singh, J; Webley, Y | 1 |
| Moriyama, T; Nakahama, H; Obata, K; Oka, K; Sugita, M | 1 |
| Maehara, Y; Ogita, K; Shimada, M; Soejima, Y; Suehiro, T; Suita, S; Taguchi, T; Takada, N | 1 |
| De Miguel, R; Giordani, C; Groppa, R; Imperiali, N; Martinez, B; Mombelli, C; Musso, CG; Navarro, M | 1 |
3 review(s) available for furosemide and tacrolimus
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
1 trial(s) available for furosemide and tacrolimus
| Article | Year |
|---|---|
Preoperative induction with tacrolimus does not have a detrimental effect on primary graft function in adult cadaveric renal transplantation.
Topics: Adult; Azathioprine; Cadaver; Dopamine; Drug Administration Schedule; Furosemide; Humans; Immunosuppressive Agents; Kidney Transplantation; Mannitol; Methylprednisolone; Prospective Studies; Tacrolimus; Tissue Donors | 1998 |
12 other study(ies) available for furosemide and tacrolimus
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine.
Topics: Adult; Age Factors; Cholesterol; Cyclosporine; Diabetes Mellitus, Type 1; Female; Furosemide; Humans; Hypercholesterolemia; Immunosuppressive Agents; Incidence; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Retrospective Studies; Sex Factors; Tacrolimus | 1998 |
Co-administration of furosemide augments tacrolimus-induced impairment in kidney function in rats.
Topics: Animals; Blood Pressure; Blood Urea Nitrogen; Body Weight; Diuretics; Drug Synergism; Furosemide; Kidney; Kidney Diseases; Rats; Rats, Sprague-Dawley; Renin; Tacrolimus | 2000 |
Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.
Topics: Acidosis, Renal Tubular; Drug Therapy, Combination; Female; Follow-Up Studies; Furosemide; Humans; Infant; Liver Transplantation; Living Donors; Risk Assessment; Severity of Illness Index; Sodium Bicarbonate; Tacrolimus; Transplantation Immunology; Treatment Outcome | 2003 |
Furosemide test in stage III-chronic kidney disease and kidney transplant patients on tacrolimus.
Topics: Adolescent; Adult; Aged; Diuretics; Female; Furosemide; Humans; Immunosuppressive Agents; Kidney Function Tests; Kidney Transplantation; Kidney Tubules; Male; Middle Aged; Potassium; Renal Insufficiency, Chronic; Tacrolimus; Young Adult | 2013 |